Skip to main content

Month: August 2020

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient from the U.S. for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.The Company is also pleased to announce that it has now enrolled 26 patients since the study began on August 5, 2020. The Phase 2b/3 study enrollment target is 150 patients, aggregated from all participating sites.“We are very pleased to announce our first U.S. patient,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We have also had steady enrollment from one of our International sites and as a result, we expect to reach 25% of our...

Continue reading

Rotmans Furniture Offers COVID-compliant “Retail Therapy” with Extended “Triple Tax Savings Sale” for Coronavirus Weary Customers

Triple Tax Savings Sale expanded from 2 days to multiple weeks for first time ever! Going on now through August 30thHuge inventory of mattresses, area rugs, designer rugs, handmade rugs in many sizes, bedrooms, dining rooms, desks, chairs, beds, and sofas perfect for home offices, virtual learning and boomerang kidsBuying partner brings buying power to Rotmans             Worcester, MA, Aug. 13, 2020 (GLOBE NEWSWIRE) — Rotmans Furniture and Flooring is providing a welcome respite and a huge price break for shoppers weary of being cooped up during the COVID shutdown and eager to get out and shop. Rotmans, a partially owned subsidiary of Vystar Corporation (OTCQB: VYST), provides the ideal “Retail Therapy” of a massive Triple Tax Savings Sale, large open spaces for easy social distancing, and an extensive inventory of hundreds of...

Continue reading

Hamilton Thorne to Announce Q2 2020 Financial Results and Hold Conference Call on August 20, 2020

BEVERLY, Mass. and TORONTO, Aug. 13, 2020 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three- and six-month periods ended June 30, 2020 before market open on Thursday, August 20, 2020. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com.The Company will follow with a conference call on the same day at 11:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations,...

Continue reading

Credicorp Ltd.: Credicorp Day: 25th Anniversary of listing in the NYSE

Lima, Aug. 13, 2020 (GLOBE NEWSWIRE) — Lima, PERU, August 13th, 2020 — Credicorp (NYSE: BAP) invites institutional investors and sell-side analysts to participate in its virtual Investor Day, commemorating Credicorp’s 25thAnniversary of its listing in the New York Stock Exchange. The event will take place on October 1s, 2020.Time:8:30 – 11:00 PET9:30 – 12:00 ET15:30 – 18:00 BTTo pre-register for the event, please visit credicorpday.comPresentation materials and a webcast replay will be available after the event concludes www.credicorpnet.comFor more information, please contact Credicorp Investor Relations at investorrelations@credicorpperu.com or Cinthya Werner, InspIR Group at +1-646-940-8843 / credicorpday@inspirgroup.comAbout CredicorpCredicorp Ltd. (NYSE: BAP) is the leading financial services holding company in Peru with...

Continue reading

Dominion Water Reserves Announces Appointment of Marie-Claude Bourgie as Interim CEO

MONTREAL, Aug. 13, 2020 (GLOBE NEWSWIRE) — Dominion Water Reserves Corp. (“DWR” or the “Company”), announces that, effective August 12, 2020, Marie-Claude Bourgie will assume the role of interim Chief Executive Officer (“CEO”) of the Company. To facilitate this change, Norman Forrest has tendered his resignation as the Company’s President and CEO, member of the Company’s board of directors (the “Board”), effective August 7, 2020.Mr. Forrest has served as the Company’s President and CEO during a critical phase of the Company’s development and presided over the listing process successfully.“We are grateful for Norman’s service to the Company and we wish him all the best in his future endeavors,” states Germain Turpin, a Director of DWR. “It’s now time to transition to a new leader with deep leadership and organizational skills...

Continue reading

Ayala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 –– On track to initiate patient dosing in Phase 2 TENACITY study of AL101 for the treatment of TNBC in 2020 –REHOVOT, Israel and WILMINGTON, Del., Aug. 13, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the second quarter ended June 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.“Our successful IPO in the second quarter represents an important step for Ayala as we work to make meaningful...

Continue reading

FitLife Brands Announces Second Quarter 2020 Results

Omaha, Aug. 13, 2020 (GLOBE NEWSWIRE) —OMAHA, NE – August 13, 2020 — FitLife Brands, Inc. (“FitLife” or the “Company”) (OTC Pink: FTLF), an international provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the brand names NDS Nutrition™, PMD®, SirenLabs®, CoreActive®, Metis Nutrition™, iSatori™, Energize, and BioGenetic Laboratories, today announced results for the three and six months ended June 30, 2020.Highlights for the second quarter ended June 30, 2020 include:Total revenue decreased 40.7% to $2.7 million driven by the impact of COVID-19 on foot traffic in our wholesale partners’ retail locations and reduced shipments to GNC in anticipation of its bankruptcy filing.Direct-to-consumer online sales increased to 41% of total revenue, compared to 13% in the same quarter...

Continue reading

Sabina Gold & Silver Announces Interim Financial Results for the Quarter Ended June 30, 2020

VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX/ SGSVF – OTCQX) reports the interim financial results for the quarter ended June 30, 2020.“During the quarter, the Company focused on preparing work plans for the remainder of 2020 and re-opening camp,” said Bruce McLeod, the Company’s President & CEO.  “Camp was re-opened in late June under a strict COVID-19 Operational Framework.  I am pleased to report that camp was re-opened efficiently and is continuing to operate safely under these new protocols.  Drilling began in early July with first results expected in the coming weeks.”The Company continues to closely assess and monitor the COVID-19 situation as it evolves and has undertaken measures to mitigate associated risks, including establishing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.